Evidence presented at the National Cancer Conference indicating that 10-15% of cancer patients treated with Taxotere will suffer permanent hair loss. “Long term significant scalp alopecia (here lasting for up to 3.5 years following completion of chemotherapy) may affect 10-15% of patients following docetaxel for EBC [early breast cancer],” the researchers said. “This appears to be unrelated to other patient and treatment characteristics. ”
